Technical Data Sheet

InVivoMAb anti-mouse TIM-3 (CD366)



Lot Specific Information

Lot Number:Lot Specific*Volume:Lot Specific*

Concentration: Lot Specific* (generally 4 to 11 mg/ml) *

Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number:BE0115Clone:RMT3-23Isotype:Rat IgG2a, κ

Recommended Isotype Control(s): InVivoMAb rat IgG2a isotype control, anti-trinitrophenol

Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer

Immunogen: Recombinant mouse TIM-3 in vivo TIM-3 neutralization

Reported Applications: in vitro TIM-3 blocking

Flow cytometry

Formulation: PBS, pH 7.0 Contains no stabilizers or preservatives

<2EU/mg (<0.002EU/μg)

Endotoxin: 22EO/Titg (<0.002EO/pg)

Determined by LAL gel clotting assay

Determined by LAL ger clotting assay

Purity: Determined by SDS-PAGE

Sterility: 0.2 µM filtered

Production: Purified from tissue culture supernatant in an animal free facility

Purification:Protein GRRID:AB_10949464Molecular Weight:150 kDa

Description

The RMT3-23 monoclonal antibody reacts with mouse TIM-3 (T cell immunoglobulin and mucin domain-3) also known as CD366. TIM-3 is a 60 kDa member of the TIM family of immune checkpoint receptors and exists as a type I transmembrane glycoprotein with a mucin-like domain in its extracellular portion and a tyrosine phosphorylation motif in its cytoplasmic portion. TIM-3 is specifically expressed at high levels on the surface of Th1 lymphocytes whereas Th2 lymphocytes express TIM-1 and TIM-2. TIM-3 activation occurs via binding to the cell-associated C-type lectin galectin-9. Upon binding TIM-3 induces apoptosis of Th1 cells. Inhibition of TIM-3 signaling in mice has been shown to exacerbate experimental autoimmune encephalomyelitis, promote IFNγ production and Th1 cell proliferation. Tim-3 has also been shown to be required for the induction of tolerance, as both TIM-3 knockout animals and mice treated with TIM-3-Ig fusion protein display defects in the induction of antigen-specific tolerance. Additionally, TIM-3 signaling is currently being explored as a cancer immunotherapy target as CD8 T cells which express both TIM-3 and PD-1 exhibit greater defects in both cell-cycle progression and effector cytokine production than cells that express PD-1 alone. The RMT3-23 antibody acts as a TIM-3 receptor antagonist and has been shown to have functional activity including suppressing tumor cell growth in a murine sarcoma model.

Shelf-life and Storage

Store at the stock concentration at 4°C. Do not freeze.

All Bio X Cell antibodies have a guaranteed shelf-life of one year from the date of customer receipt when stored as recommended. It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at bxcell.com/faqs.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

Bio X Cell, Inc.

bxcell.com 1.866.787.3444

customerservice@bxcell.com

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.

Bio X Cell, Bio X Cell Logo and all other trademarks are the property of Bio X Cell, Inc. © 2020 Bio X Cell

For a complete list of references, visit $\underline{\text{https://bxcell.com/product/m-tim-3/\#references}} \text{ or scan the QR code below.}$



Bio X Cell, Inc.

bxcell.com

1.866.787.3444

customerservice@bxcell.com

Conditions: For Research Use Only. Not for use in diagnostic or therapeutic procedures. Not for resale.